The efficacy of first-line chemotherapy in endocrine-resistant hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer.

PURPOSE: Combinations of endocrine therapy (ET) and targeted therapy (CDK4/6 or mTOR inhibitors) are standard of care for HR+/HER2- metastatic breast cancer (MBC). When ET is not effective, chemotherapy is commonly used. However, clinical outcomes of chemotherapy in the endocrine-resistant setting a...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Breast Cancer Res Treat
Auteurs principaux: Chainitikun, Sudpreeda, Long, James P, Rodriguez-Bautista, Ruben, Iwase, Toshiaki, Tripathy, Debu, Fujii, Takeo, Ueno, Naoto T.
Format: Artigo
Langue:Inglês
Publié: 2020
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7501162/
https://ncbi.nlm.nih.gov/pubmed/32720114
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-020-05837-6
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires